329967-16-0Relevant academic research and scientific papers
Aminosuberoyl hydroxamic acids (ASHAs): A potent new class of HDAC inhibitors
Belvedere, Sandro,Witter, David J.,Yan, Jiaming,Secrist, J. Paul,Richon, Victoria,Miller, Thomas A.
, p. 3969 - 3971 (2008/02/09)
Histone deacetylase (HDAC) inhibitors that target Class I and Class II HDACs are currently in advanced clinical trials for the treatment of cancer. Vorinostat (Zolinza, SAHA) is a hydroxamic acid approved for the treatment of patients with cutaneous T-cel
HISTONE DEACETYLASE INHIBITORS
-
Page/Page column 51-52, (2008/06/13)
This invention relates to hydroxamic acid derivatives having a urea linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic
HISTONE DEACETYLASE INHIBITORS
-
Page/Page column 50, (2008/06/13)
This invention relates to hydroxamic acid derivatives having a carbamate linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, alle
HISTONE DEACETYLASE INHIBITORS
-
Page/Page column 52, (2008/06/13)
This invention relates to hydroxamic acid derivatives having a sulfonamide linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, al
